Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension
Status:
Unknown status
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In this research study, the goal is to find out if a currently FDA-approved medication called
Tekturna(Aliskiren) along with the addition of Vitamin D will lower blood pressure and
improve heart function in the African American population. High blood pressure occurs earlier
in life in African Americans, is more severe, and is associated with greater organ damage in
relation to uncontrolled hypertension. Having low levels of Vitamin D is also very common in
the African American population. Research has shown that there may be a link between low
Vitamin D levels and the ability of high blood pressure medications to be fully effective.
Phase:
Phase 4
Details
Lead Sponsor:
Wayne State University
Collaborator:
Novartis
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins